Do guidelines for community-acquired pneumonia improve the cost-effectiveness of hospital care?

Clinical Infectious Diseases

Volumn 32, Issue 5, 2001, Pages 728-741

  Davey, Peter ^b   Barlow, Gavin ^a   Rubinstein, Ethan ^c  

^a NHS TAYSIDE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CAREGIVER; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; HEALTH CARE PERSONNEL; HOSPITAL CARE; HUMAN; PATIENT ATTITUDE; PATIENT CARE; PATIENT SELECTION; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

COMMUNITY-ACQUIRED INFECTIONS; COST-BENEFIT ANALYSIS; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; PNEUMONIA; PRACTICE GUIDELINES; TREATMENT OUTCOME;

EID: 0035282378     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/319216     Document Type: Review

References (103)

1. The management of infections and antibiotic therapy: A European survey
2. Antibiotic treatment of community-acquired pneumonia in clinical practice: A European perspective
3. Initial antibiotic therapy for lower respiratory tract infection in the community: A European survey
4. Benchmark analysis of strategies hospitals use to control antimicrobial expenditures
5. Antimicrobial misuse in patients with positive blood cultures
6. Use of antibiotics: A brief exposition of the problem and some tentative solutions
7. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy
8. Community-acquired pneumonia in adults: Guidelines for management
9. Community-acquired pneumonia guidelines - An international comparison: A view from Europe
10. Community-acquired pneumonia in adults in British hospitals in 1982-1983: A survey of aetiology, mortality, prognostic factors and outcome
11. How to ensure that guidelines are effective
12. Quality of health care. 2. Measuring quality of care
13. Why don't physicians follow clinical practice guidelines? A framework for improvement
14. Practice guidelines developed by specialty societies: The need for a critical appraisal
15. Development of practice guidelines
16. Effects of the National Institutes of Health Consensus Development Program on physician practice
17. Clinical guidelines: Proliferation and medicolegal significance
18. Empirical therapy for nonhospitalized patients with community-acquired pneumonia
19. Community-acquired pneumonia: The annual cost to the National Health Service in the UK
20. Frequency of subspecialty physician care for elderly patients with community-acquired pneumonia
21. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community
22. Use of investigations in lower respiratory tract infection in the community: A European survey
23. Ambulatory patients with community-acquired pneumonia: The frequency of atypical agents and clinical course
24. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination
25. Patients hospitalized after initial outpatient treatment for community-acquired pneumonia
26. Clinical signs of pneumonia in children
27. Implementing antibiotic practice guidelines through computer-assisted decision support: Clinical and financial outcomes
28. Understanding physician adherence with a pneumonia practice guideline: Effects of patient, system, and physician factors
29. Safely increasing the proportion of patients with community-acquired pneumonia treated as ouypatients: An interventional trial
30. Comparison of physician judgment and decision aids for ordering chest radiographs for pneumonia in outpatients
31. Older persons' perceptions of home and hospital as sites of treatment for acute illness
32. Improving preventive care by prompting physician
33. Impact of formal continuing medical education: Do conferences, workshops, rounds, and other traditional continuing education activities change physician behavior or health care outcomes?
34. Pediatricians' attitudes, beliefs, and practices regarding clinical practice guidelines: A national survey
35. Statistical association and cause-effect relationships
36. Spectrophotometric assessment of dose-response curves for single antimicrobial agents and antimicrobiai combination
37. Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection
38. Quality of care improvements for patients with pneumonia
39. Dose response of experimental pseudomonas endophthalmitis to ciprofloxacin, gentamicin and imipenem: Evidence for resistance to "late" treatment of infections
40. Tolerance of Pseudomonas aeruginosa to killing by ciprofloxacin, gentamicin and imipenem in vitro and in vivo
41. Measuring quality of care with explicit process criteria before and after implementation of the DRG-based prospective payment system
42. Quality of care, process, and outcomes in elderly patients with pneumonia
43. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia
44. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia
45. Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia
46. An analysis of community and hospitai acquired bacteraemia in a large teaching hospital in the United Kingdom
47. Gram-negative bacteraemia: Re-evaluation of clinical features and treatment in 612 patients
48. Antibiotic therapy and outcome of monomicrobial gram-negative bacteraemia: A 3-year population-based study
49. Role of pharmacokinetics in the outcome of infections
50. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
51. Antibiotic treatment for surgical peritonitis
52. Initial microbiologic studies did not affect outcome in adults hospitalized with community-acquired pneumonia
53. Influence of blood culture results on antiblotic choice in the treatment of bacteremia
54. Clinical implications of positive blood cultures
55. Antimicrobial therapy of septicemic patients in intensive care units before and after blood culture reporting
56. The impact of the first notification of positive blood cultures on antibiotic therapy: A one-year survey
57. Clinical impact of rapid identification and susceptibility testing of bacterial blood culture isolates
58. Pneumonia with serological evidence of acute infection with the Chlamydia-like microorganism "Z."
59. Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: A comparison between chlamydial and pneumococcal pneumonia
60. Multiple pathogens in adult patients admitted with community-acquired pneumonia: A one year prospective study of 346 consecutive patients
61. Clinical practice guidelines for the management of pneumonia: Do they work?
62. Critical pathways or treatment algorithms in infectious diseases: Do they really work?
63. On-site physician staffing in a community hospital intensive care unit: Impact on test and procedure use and on patient outcome
64. Variations in antimicrobial use and cost in more than 2,000 patients with community-acquired pneumonia
65. Should third-generation cephalosporins be the empirical treatment of choice for severe community-acquired pneumonia in adults?
66. Relationship of provider characteristics to outcomes, process, and costs of care for community-acquired pneumonia
67. Variation in lengtb of hospital stay in patients with community-acquired pneumonia: Are shorter stays associated with worse medical outcomes?
68. The hospital discharge decision for patients with community-acquired pneumonia: Results from the Pneumonia Patient Outcomes Research Team cohort study
69. Time to clinical stability in patients hospitalized with community-acquired pneumonia: Implications for practice guidelines
70. A prospective randomized study of inpatient intravenous antibiotics for community-acquired pneumonia: The optimal duration of therapy
71. Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: Open, randomised controlled trial
72. Why do patients with infection remain in hospital once changed to oral antibiotics?
73. The clinical utility of a day of hospital observation after switching from intravenous to oral antibiotic therapy in the treatment of pyelonephritis
74. The clinical benefit of in-hospital observation in "low-risk" pneumonia patients after conversion from parenteral to oral antimicrobial therapy
75. Pharmacoeconomics and drug prescribing
76. Use of critical pathways to improve the care of patients with acute myocardial infarction
77. Improving drug prescribing in primary care: A critical analysis of the experimental literature
78. Medical outcomes and antimicrobial cost with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia
79. The best treatment for pneumonia: New clues, but no definitive answers
80. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study investigators. Community-acquired pneumonia intervention trial assessing levofloxacin
81. Use of a treatment protocol in the management of community-acquired lower respiratory infection
82. Pneumonia mortality reduction and quality improvement in a community hospital
83. Antibiotic misuse in two clinical situations: Positive blood culture and administration of aminoglycosides
84. Empiric antibiotic treatment and the misuse of culture results and antibiotic sensitivities in patients with community-acquired bacteraemia due to urinary tract infection
85. Computerized clinical practice guidelines for review of antibiotic therapy for bacteremia
86. Impact of infection consultation service for bacteremia on clinical management and use of resources
87. Why is evaluation of the cost effectiveness of audit so difficult? The example of thrombolysis for suspected acute myocardial infarction
88. A pro-spective, multicenter study of a pneumonia practice guideline
89. All changed, changed utterly: British medicine will be transformed by the Bristol case
90. Enhancing performance measurement: NCQA's road map for a health information framework
91. Performance measurement: Problems and solutions
92. Intravenous antimicrobial therapy in the community: Underused, inadequately resourced or irrelevant to UK healthcare?
93. A framework for incorporating cost-effectiveness in evidence-based clinical practice guidelines
94. The number needed to treat: A clinically useful measure of treatment effect
95. Community acquired pneumonia: Aetiology and usefulness of severity criteria on admission
96. Hospitalized pneumonia: Outcomes, treatment patterns, and costs in urban and rural areas